14,858, while the minimum investment for High-Net-Worth Individuals (HNIs) is 14 lots (532 shares), amounting to ₹ 208,012.

Equirus Capital Private Limited, Ambit Private Limited and Nuvama Wealth Management Limited are the book-running lead manager while Link Intime India Private Limited is the registrar for the Issue. 

Senores Pharmaceuticals Limited IPO GMP Today
The Grey Market Premium of Senores Pharmaceuticals Limited IPO is expected to be ₹176 based on the financial performance of the company. No real trading is done on the basis of Grey Market Premium that's why no real discovery of price can be done before the listing of shares on the stock exchange. The Grey Market Premium totally depends upon the Demand and Supply of the shares of the company in unorganized manner which is not recommended. The Grey Market Premium is mentioned for educational and informational purposes only.

Senores Pharmaceuticals Limited Day Wise IPO GMP Trend 

   

Date	IPO Price	Expected Listing Price	GMP	Last Updated
23 December 2024	₹ 391	₹567	₹ 176 (45.01%)	07:00 PM; 23 Dec 2024
22 December 2024	₹ 391	₹547	₹ 156 (39.95%)	07:00 PM; 22 Dec 2024
21 December 2024	₹ 391	₹547	₹ 156 (39.95%)	02:44 PM; 21 Dec 2024
19 December 2024	₹ 391	₹ 497	₹ 106 (27.15%)	05:00 PM; 19 Dec 2024

Senores Pharmaceuticals Limited IPO Live Subscription Status Today: Real-Time Updates
As of 07:00 on 24 December 2024, the Senores Pharmaceuticals IPO live subscription status shows that the IPO subscribed 93.69 times on its Final day of subscription period. Check the Senores Pharmaceuticals IPO Live Subscription Status Today at BSE.

Senores Pharmaceuticals IPO Anchor Investors Report
Senores Pharmaceuticals has raised ₹260.63 Crores from Anchor Investors at a price of ₹391 per shares in consultation of the Book Running Lead Managers. The company allocate 66,65,725 equity shares to the Anchor Investors. Check Full List of Senores Pharmaceuticals Anchor Investor List.

Note:- Equity Shares allotted to Anchor Investors (if any) are allotted from Qualified Institutional Buyers (QIBs) reservation portion.
Note:- The Number of shares offered shown IPO subscription section table is calculated at the lower end of the price band and Number of shares calculated in IPO details table section is calculated at upper end of the price band in case of Book Building Issue, so there can be difference. This is because we assume shares will be issued by the company at upper band as Anchor Investors also subscribe at upper band and shares will be issued at lower band only if in case of undersubscription of IPO.
Note:- Market Maker portion (if any) are not shown separately in subscription table and included in NIIs reservation portion

Senores Pharmaceuticals Limited IPO Allotment Date - Step by Step Guide to Check Allotment Status Online
Senores Pharmaceuticals IPO allotment date is 26 December, 2024, Thursday. Senores Pharmaceuticals IPO Allotment will be out on 26th December 2024 and will be live on Registrar Website from the allotment date. Check Senores Pharmaceuticals IPO Allotment Status here. Here's how you can check the allotment status:
- Navigate to the IPO allotment status page.
- Select Senores Pharmaceuticals Limited IPO from the dropdown list of IPOs.
- Enter your application number, PAN, or DP Client ID.
- Submit the details to check your allotment status.
By following either of these methods, investors can quickly determine their allotment status and proceed accordingly with their investments.

Objectives of Senores Pharmaceuticals Limited IPO
Senores Pharmaceuticals proposes to utilise the Net Proceeds towards the following objects: 
1. ₹1,070.00 Million is required for Investment in one of their Subsidiaries, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in their Atlanta Facility;
2. ₹734.80 Million is required for Re-payment/pre-payment, in full or in part, of certain borrowings availed by their Company;
3. ₹202.20 Million is required for Investment in their Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiary;
4. ₹432.59 Million is required for Funding the working capital requirements of the Company;
5. ₹594.83 Million is required for Investment in our Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”) and Ratnatris Pharmaceutical Private Limited (“Ratnatris”) to fund their working capital requirements; and
6. Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.

Refer to Senores Pharmaceuticals Limited RHP for more details about the Company.

-->